UTD2 and Capecitabine for high-risk TNBC after chemo
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding UTD2 to capecitabine works better than capecitabine alone for triple-negative breast cancer that didn't completely disappear after chemo. It's for patients who had surgery and are at risk of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You completed at least 4 cycles of chemo (anthracycline or taxane) before surgery, but your cancer didn't fully go away.
- You had surgery to remove all visible cancer, and the edges were cancer-free.
- Your cancer is triple-negative (ER, PR, and HER2-negative) based on tests after surgery.
- You haven't received other cancer medicines (except radiation) after your surgery.
- Your overall health is good (ECOG 0-1) and your blood counts, liver, and kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial tests a chemotherapy drug called utidelone given before surgery to shrink high-risk or locally advanced breast cancer. It may help make surgery more effective.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.